

## Special Issue

# Recent Scientific Advances in Vaccination against Ebola and Marburg Virus Diseases

### Message from the Guest Editor

The Ebola and Marburg virus diseases are severe haemorrhagic fevers affecting people and non-human primates (NHP) with a high case fatality rate. Due to climate and environmental change leading to increasing interactions between humans and wildlife hosts, EVD and MVD outbreaks could become more frequent. It is therefore extremely important to develop and reinforce prevention and control strategies in at-risk countries to limit the extent of current and future outbreaks.

Vaccines play a key role in the response to epidemic threats and have been an important part of the response to EVD outbreaks due to *Zaire ebolavirus* since the 2014–16 West African outbreak. There are no licensed vaccines against Sudan and Marburg virus, although several candidates are under development. This Special Issue aims to collect recent scientific knowledge and advances in vaccination against Ebola and Marburg virus diseases. We are interested in a broad area of research, including clinical trials, vaccine roll-out strategies, mathematical modelling, NHP studies and literature reviews, which can inform future vaccination strategies against EVD and MVD.

---

### Guest Editor

Dr. Daniela Manno

Department of Nutrition and Public Health Intervention Research,  
London School of Hygiene and Tropical Medicine (LSHTM), Keppel  
Street, London WC1E 7HT, UK

---

### Deadline for manuscript submissions

closed (31 August 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/154780](https://mdpi.com/si/154780)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).